Abstract

Hypertrophic cardiomyopathy (HCM) is a common genetic disorder characterized by left ventricular hypertrophy and cardiac hyper-contractility. Mutations in the β-cardiac myosin heavy chain gene (β-MyHC) are a major cause of HCM, but the specific mechanistic changes to myosin function that lead to this disease remain incompletely understood. Predicting the severity of any β-MyHC mutation is hindered by a lack of detailed examinations at the molecular level. Moreover, because HCM can take ≥20 years to develop, the severity of the mutations must be somewhat subtle. We hypothesized that mutations that result in early onset disease would have more severe changes in function than do later onset mutations. Here, we performed steady-state and transient kinetic analyses of myosins carrying one of seven missense mutations in the motor domain. Of these seven, four were previously identified in early onset cardiomyopathy screens. We used the parameters derived from these analyses to model the ATP-driven cross-bridge cycle. Contrary to our hypothesis, the results indicated no clear differences between early and late onset HCM mutations. Despite the lack of distinction between early and late onset HCM, the predicted occupancy of the force-holding actin·myosin·ADP complex at [Actin] = 3 Kapp along with the closely related duty ratio (the fraction of myosin in strongly attached force-holding states), and the measured ATPases all changed in parallel (in both sign and degree of change) compared with wildtype (WT) values. Six of the seven HCM mutations were clearly distinct from a set of previously characterized DCM mutations.

Highlights

  • Hypertrophic cardiomyopathy (HCM) is a common genetic disorder characterized by left ventricular hypertrophy and cardiac hyper-contractility

  • The most common inherited cardiovascular disease is hypertrophic cardiomyopathy (HCM)4 with a disease prevalence of 1:250 –500 [1, 2]. Excluding those with a history of hypertension, aortic stenosis, other pre-existing systemic diseases, or being a world-class athlete, HCM is diagnosed as unexplained left ventricular hypertrophy and is typically accompanied by diastolic dysfunction [3]

  • We compared the properties of known adult pathogenic HCM mutations (R719W, R723G, and G741R) with novel sporadic mutations that had appeared in recent cardiomyopathy screens as specific to early onset patients (H251N, D382Y, P710R, and V763M) [9, 10]

Read more

Summary

Results

We produced recombinant mutant and WT human myosin motors in differentiated C2C12 muscle cells, performed extensive kinetic analysis, and evaluated the severity of these mutations based on alterations to the cross-bridge cycle. Region utilizing the short subfragment 1 (sS1, corresponding to residues 1– 808, Fig. S1)

ATPase activity
Transient kinetics data summary
Modeling the ATPase cycle of HCM mutant motors
Discussion
Expression and purification of proteins
Transient kinetics
Modeling analysis
Analysis of errors in the modeling
In vitro motility

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.